347 related articles for article (PubMed ID: 34592164)
1. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
4. Statins in Graves Orbitopathy: A New Therapeutic Tool.
Lanzolla G; Comi S; Cosentino G; Pakdel F; Marinò M
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S29-S39. PubMed ID: 38054983
[TBL] [Abstract][Full Text] [Related]
5. Natural history of graves' orbitopathy after treatment.
Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
[TBL] [Abstract][Full Text] [Related]
7. Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.
Covelli D; Vannucchi G; Campi I; Currò N; D'Ambrosio R; Maggioni M; Gianelli U; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2015 May; 100(5):1731-7. PubMed ID: 25751109
[TBL] [Abstract][Full Text] [Related]
8. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
9. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus as a second-line treatment for Graves' orbitopathy.
Lanzolla G; Maglionico MN; Comi S; Menconi F; Piaggi P; Posarelli C; Figus M; Marcocci C; Marinò M
J Endocrinol Invest; 2022 Nov; 45(11):2171-2180. PubMed ID: 35831587
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial.
Ye X; Zhao H; Liu J; Lu B; Shao J; Wang J
Eur J Endocrinol; 2021 Feb; 184(2):277-287. PubMed ID: 33539318
[TBL] [Abstract][Full Text] [Related]
12. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
14. Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy-Preliminary Results From a Prospective Single-Center Study.
Sarnat-Kucharczyk M; Świerkot M; Handzlik G; Kulawik G; Jagoda K; Grochoła-Małecka I; Fryżewska J; Mrukwa-Kominek E; Chudek J
Front Endocrinol (Lausanne); 2022; 13():871009. PubMed ID: 35615718
[TBL] [Abstract][Full Text] [Related]
15. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?
Bartalena L; Veronesi G; Krassas GE; Wiersinga WM; Marcocci C; Marinò M; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G; Perros P; Kahaly GJ;
J Endocrinol Invest; 2017 May; 40(5):547-553. PubMed ID: 28176220
[TBL] [Abstract][Full Text] [Related]
16. A pilot study on the use of prednisolone-encapsulated liposomes for the treatment of moderate-to-severe Graves' orbitopathy with reduced systemic steroid exposure.
Detiger SE; Kremer TM; A S H Dalm V; de Keizer ROB; Wubbels RJ; Metselaar JM; van Hagen PM; Peeters RP; Paridaens D
Acta Ophthalmol; 2021 Nov; 99(7):797-804. PubMed ID: 33423386
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and Side Effects of Lateral Orbital Wall Decompression Including the Orbital Rim in Patients with Graves' Orbitopathy].
Horn M; Schittkowski MP
Klin Monbl Augenheilkd; 2019 Jan; 236(1):17-24. PubMed ID: 30690696
[TBL] [Abstract][Full Text] [Related]
18. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
19. Effect of systemic steroid therapy in Graves' orbitopathy on regulatory T cells and Th17/Treg ratio.
Siomkajło M; Mizera Ł; Szymczak D; Kolačkov K; Grzegrzółka J; Bolanowski M; Daroszewski J
J Endocrinol Invest; 2021 Nov; 44(11):2475-2484. PubMed ID: 33866536
[TBL] [Abstract][Full Text] [Related]
20. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
